Founded in 2004, ERYTECH Pharma develops innovative cancer therapies that work by starving tumours. Its first product, which is in phase III development, provides a therapeutic solution to frail patients with acute leukaemia.
ERYTECH proprietary technology is based on encapsulation of therapeutic molecules into red blood cells.
The company has a production unit located in Lyons with “Pharmaceutical Establishment” status. It has signed two distribution partnership agreements with the Orphan Europe-Recordati company and the TEVA group.
ERYTECH reports positive Phase III results from its pivotal study with GRASPA® in Acute Lymphoblastic Leukemia.
ERYTECH provides a business update and reports its financial results for the period ending June 30, 2014.
ERYTECH Pharma announces that an independent Data and Safety Monitoring Board (DSMB) completed its second safety assessment of the company’s Phase IIb study in Acute Myeloid Leukemia (AML) and unanimously recommended continuation of the trial without modification.
ERYTECH Pharma announces the enrollment of the first patient in its Phase II study with ERY-ASP in second line treatment of patients affected by pancreatic cancer.
FINANCE – ERYTECH Pharma participates in Actionaria 2014 on November 21 & 22, 2014 in Paris, France.
FINANCE – ERYTECH Pharma takes part in Jefferies Global Healthcare Conference on November 19 & 20, 2014 in London, UK.
ERYTECH Pharma participates in Bio Europe 2014 from November 3 to 5 in Frankfurt, Germany.
FINANCE – ERYTECH Pharma takes part in CF&B Large & Midcap Event which takes place on October 2 & 3, 2014 in Paris, France.